Search

Your search keyword '"Pancheva, Ruzha"' showing total 21 results
Start Over Author "Pancheva, Ruzha"
21 results on '"Pancheva, Ruzha"'

1. A randomized controlled trial protocol for the introduction of a multidisciplinary individualized nutritional intervention in children with cerebral palsy

Author

Pancheva, Ruzha, Fitneva, Stanka A., Chamova, Rositsa, Marinov, Dimitar, Toneva, Albena, Hadzhieva, Stanislava, Braykova, Rozalina, Yoncheva, Nikoleta, Tsvetanova, Stefka, Nikolova, Silviya, Usheva, Natalya, Huysentruyt, Koen, Dimova, Karina, Bocheva, Yana, Pavlova, Stanislava, and Hristanova, Petya

Published
2024
Full Text
View/download PDF

7. Vaccine confidence among parents: Large scale study in eighteen European countries

Author

Hadjipanayis, Adamos, primary, van Esso, Diego, additional, del Torso, Stefano, additional, Dornbusch, Hans Jürgen, additional, Michailidou, Kyriaki, additional, Minicuci, Nadia, additional, Pancheva, Ruzha, additional, Mujkic, Aida, additional, Geitmann, Karin, additional, Syridou, Garyfallia, additional, Altorjai, Peter, additional, Pasinato, Angela, additional, Valiulis, Arunas, additional, Soler, Paul, additional, Cirstea, Olga, additional, Illy, Károly, additional, Mollema, Liesbeth, additional, Mazur, Artur, additional, Neves, Ana, additional, Zavrsnik, Jernej, additional, Lapii, Fedir, additional, Efstathiou, Elisavet, additional, Kamphuis, Mascha, additional, and Grossman, Zachi, additional

Published
2020
Full Text
View/download PDF

8. Mortality in childhood-onset type 1 diabetes

Author

Hadzhieva, Elitsa, primary, Boyadzhieva, Mila, additional, Iotova, Violeta, additional, Galcheva, Sonya, additional, Tsochev, Kaloyan, additional, Chalykova, Tatiana, additional, Yotov, Yoto, additional, Balev, Boyan, additional, Bocheva, Yana, additional, Usheva, Nataliya, additional, and Pancheva, Ruzha, additional

Published
2019
Full Text
View/download PDF

11. Malnutrition in Children with Neurodevelopmental Disorders and Disabilities in North-eastern Bulgaria

Author

Pancheva, Ruzha, Toneva, Albena, Nikolova, Silviya, Rangelova, Lalka Stefanova, Morfova, Aneta, Konstantinova, Desislava, Pancheva, Ruzha, Toneva, Albena, Nikolova, Silviya, Rangelova, Lalka Stefanova, Morfova, Aneta, and Konstantinova, Desislava

Abstract

Background: Malnutrition in children with neurodevelopmental disorders and disabilities (NDD/D) is an issue of a growing attention in academic community. Until recently, it was commonly considered that almost every neurological disability was accompanied by a problem of malnutrition. Objective: The aim is to assess the nutritional status of children with NDD/D in North-eastern Bulgaria through various anthropometric measurements. Methods: A survey conducted in the period of April 2017 to April 2018 included 109 children with NDD/D from North-eastern Bulgaria. Questionnaires on socio-demographic data, gross motor skills, nutrition specifics and quality of life were applied, along with an anthropometric measurement of the children. Assessment of nutritional status was made by standards and criteria of World Health Organization (WHO) and American Society for Parenteral and Enteral Nutrition (ASPEN). Results: The results manifests a high relative share of malnutrition, with underweight cases of 44.9% (weight-for-age  ? 2Z), stunted

Published
2019

13. Microbial Preparations (Probiotics) for the Prevention of Clostridium difficile Infection in Adults and Children: An Individual Patient Data Meta-analysis of 6,851 Participants

Author

Johnston, Bradley C., primary, Lytvyn, Lyubov, additional, Lo, Calvin Ka-Fung, additional, Allen, Stephen J., additional, Wang, Duolao, additional, Szajewska, Hania, additional, Miller, Mark, additional, Ehrhardt, Stephan, additional, Sampalis, John, additional, Duman, Deniz G., additional, Pozzoni, Pietro, additional, Colli, Agostino, additional, Lönnermark, Elisabet, additional, Selinger, Christian P., additional, Wong, Samford, additional, Plummer, Susan, additional, Hickson, Mary, additional, Pancheva, Ruzha, additional, Hirsch, Sandra, additional, Klarin, Bengt, additional, Goldenberg, Joshua Z, additional, Wang, Li, additional, Mbuagbauw, Lawrence, additional, Foster, Gary, additional, Maw, Anna, additional, Sadeghirad, Behnam, additional, Thabane, Lehana, additional, and Mertz, Dominik, additional

Published
2018
Full Text
View/download PDF

14. Highlights of the ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants and children with cystic fibrosis

Author

Wilschanski, Michael, Braegger, Christian P, Colombo, Carla, Declercq, Dimitri, Morton, Alison, Pancheva, Ruzha, Robberecht, Eddy, Stern, Martin, Strandvik, Birgitta, Wolfe, Sue, Schneider, Stephane M, Wilschanski, Michael, Braegger, Christian P, Colombo, Carla, Declercq, Dimitri, Morton, Alison, Pancheva, Ruzha, Robberecht, Eddy, Stern, Martin, Strandvik, Birgitta, Wolfe, Sue, and Schneider, Stephane M

Published
2016

15. Highlights of the ESPEN‐ESPGHAN‐ECFS Guidelines on Nutrition Care for Infants and Children With Cystic Fibrosis

Author

Wilschanski, Michael, primary, Braegger, Christian P., additional, Colombo, Carla, additional, Declercq, Dimitri, additional, Morton, Alison, additional, Pancheva, Ruzha, additional, Robberecht, Eddy, additional, Stern, Martin, additional, Strandvik, Birgitta, additional, Wolfe, Sue, additional, and Schneider, Stephane M., additional

Published
2016
Full Text
View/download PDF

17. Microbial Preparations (Probiotics) for the Prevention of Clostridium difficileInfection in Adults and Children: An Individual Patient Data Meta-analysis of 6,851 Participants

Author

Johnston, Bradley C., Lytvyn, Lyubov, Lo, Calvin Ka-Fung, Allen, Stephen J., Wang, Duolao, Szajewska, Hania, Miller, Mark, Ehrhardt, Stephan, Sampalis, John, Duman, Deniz G., Pozzoni, Pietro, Colli, Agostino, Lönnermark, Elisabet, Selinger, Christian P., Wong, Samford, Plummer, Susan, Hickson, Mary, Pancheva, Ruzha, Hirsch, Sandra, Klarin, Bengt, Goldenberg, Joshua Z, Wang, Li, Mbuagbauw, Lawrence, Foster, Gary, Maw, Anna, Sadeghirad, Behnam, Thabane, Lehana, and Mertz, Dominik

Abstract

OBJECTIVETo determine whether probiotic prophylaxes reduce the odds of Clostridium difficileinfection (CDI) in adults and children.DESIGNIndividual participant data (IPD) meta-analysis of randomized controlled trials (RCTs), adjusting for risk factors.METHODSWe searched 6 databases and 11 grey literature sources from inception to April 2016. We identified 32 RCTs (n=8,713); among them, 18 RCTs provided IPD (n=6,851 participants) comparing probiotic prophylaxis to placebo or no treatment (standard care). One reviewer prepared the IPD, and 2 reviewers extracted data, rated study quality, and graded evidence quality.RESULTSProbiotics reduced CDI odds in the unadjusted model (n=6,645; odds ratio [OR] 0.37; 95% confidence interval [CI], 0.25–0.55) and the adjusted model (n=5,074; OR, 0.35; 95% CI, 0.23–0.55). Using 2 or more antibiotics increased the odds of CDI (OR, 2.20; 95% CI, 1.11–4.37), whereas age, sex, hospitalization status, and high-risk antibiotic exposure did not. Adjusted subgroup analyses suggested that, compared to no probiotics, multispecies probiotics were more beneficial than single-species probiotics, as was using probiotics in clinical settings where the CDI risk is ≥5%. Of 18 studies, 14 reported adverse events. In 11 of these 14 studies, the adverse events were retained in the adjusted model. Odds for serious adverse events were similar for both groups in the unadjusted analyses (n=4,990; OR, 1.06; 95% CI, 0.89–1.26) and adjusted analyses (n=4,718; OR, 1.06; 95% CI, 0.89–1.28). Missing outcome data for CDI ranged from 0% to 25.8%. Our analyses were robust to a sensitivity analysis for missingness.CONCLUSIONSModerate quality (ie, certainty) evidence suggests that probiotic prophylaxis may be a useful and safe CDI prevention strategy, particularly among participants taking 2 or more antibiotics and in hospital settings where the risk of CDI is ≥5%.TRIAL REGISTRATIONPROSPERO 2015 identifier: CRD42015015701Infect Control Hosp Epidemiol2018;771–781

Published
2018
Full Text
View/download PDF

19. Microbial Preparations (Probiotics) for the Prevention of Clostridium difficile Infection in Adults and Children: An Individual Patient Data Meta-analysis of 6,851 Participants

Author

Lawrence Mbuagbauw, Ruzha Pancheva, Behnam Sadeghirad, Gary Foster, Joshua Z. Goldenberg, Li Wang, Dominik Mertz, Agostino Colli, Duolao Wang, Mark A. Miller, Bradley C. Johnston, Mary Hickson, Stephen Allen, Sandra Hirsch, Christian P. Selinger, Anna M. Maw, Calvin Ka-Fung Lo, Pietro Pozzoni, Lehana Thabane, Elisabet Lönnermark, Stephan Ehrhardt, John S. Sampalis, Samford Wong, Lyubov Lytvyn, Sue Plummer, Bengt Klarin, Hania Szajewska, Deniz Güney Duman, Johnston, Bradley C., Lytvyn, Lyubov, Lo, Calvin Ka-Fung, Allen, Stephen J., Wang, Duolao, Szajewska, Hania, Miller, Mark, Ehrhardt, Stephan, Sampalis, John, Duman, Deniz G., Pozzoni, Pietro, Colli, Agostino, Lonnermark, Elisabet, Selinger, Christian P., Wong, Samford, Plummer, Susan, Hickson, Mary, Pancheva, Ruzha, Hirsch, Sandra, Klarin, Bengt, Goldenberg, Joshua Z., Wang, Li, Mbuagbaw, Lawrence, Foster, Gary, Maw, Anna, Sadeghirad, Behnam, Thabane, Lehana, and Mertz, Dominik

Subjects
Microbiology (medical), Adult, Male, medicine.medical_specialty, Adolescent, Epidemiology, Placebo-controlled study, DIAGNOSIS, law.invention, 03 medical and health sciences, DOUBLE-BLIND, Young Adult, 0302 clinical medicine, Randomized controlled trial, APPROPRIATE, law, Risk Factors, Internal medicine, medicine, ANTIBIOTIC-ASSOCIATED DIARRHEA, Humans, 030212 general & internal medicine, Adverse effect, Child, SACCHAROMYCES-BOULARDII, Aged, Randomized Controlled Trials as Topic, OUTCOMES, Cross Infection, business.industry, Probiotics, Infant, Odds ratio, Middle Aged, EFFICACY, Confidence interval, Anti-Bacterial Agents, Infectious Diseases, Meta-analysis, Child, Preschool, Clostridium Infections, 030211 gastroenterology & hepatology, TRIAL, Female, Antibiotic-associated diarrhea, business, CONSENSUS, BURDEN
Abstract

OBJECTIVETo determine whether probiotic prophylaxes reduce the odds ofClostridium difficileinfection (CDI) in adults and children.DESIGNIndividual participant data (IPD) meta-analysis of randomized controlled trials (RCTs), adjusting for risk factors.METHODSWe searched 6 databases and 11 grey literature sources from inception to April 2016. We identified 32 RCTs (n=8,713); among them, 18 RCTs provided IPD (n=6,851 participants) comparing probiotic prophylaxis to placebo or no treatment (standard care). One reviewer prepared the IPD, and 2 reviewers extracted data, rated study quality, and graded evidence quality.RESULTSProbiotics reduced CDI odds in the unadjusted model (n=6,645; odds ratio [OR] 0.37; 95% confidence interval [CI], 0.25–0.55) and the adjusted model (n=5,074; OR, 0.35; 95% CI, 0.23–0.55). Using 2 or more antibiotics increased the odds of CDI (OR, 2.20; 95% CI, 1.11–4.37), whereas age, sex, hospitalization status, and high-risk antibiotic exposure did not. Adjusted subgroup analyses suggested that, compared to no probiotics, multispecies probiotics were more beneficial than single-species probiotics, as was using probiotics in clinical settings where the CDI risk is ≥5%. Of 18 studies, 14 reported adverse events. In 11 of these 14 studies, the adverse events were retained in the adjusted model. Odds for serious adverse events were similar for both groups in the unadjusted analyses (n=4,990; OR, 1.06; 95% CI, 0.89–1.26) and adjusted analyses (n=4,718; OR, 1.06; 95% CI, 0.89–1.28). Missing outcome data for CDI ranged from 0% to 25.8%. Our analyses were robust to a sensitivity analysis for missingness.CONCLUSIONSModerate quality (ie, certainty) evidence suggests that probiotic prophylaxis may be a useful and safe CDI prevention strategy, particularly among participants taking 2 or more antibiotics and in hospital settings where the risk of CDI is ≥5%.TRIAL REGISTRATIONPROSPERO 2015 identifier: CRD42015015701Infect Control Hosp Epidemiol2018;771–781

Published
2018

20. Taste disorders in patients with end-stage chronic kidney disease.

Author

Konstantinova D, Nenova-Nogalcheva A, Pancheva R, Alexandrova Y, and Pechalova P

Subjects
Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Self Report, Young Adult, Kidney Failure, Chronic complications, Taste Disorders etiology
Abstract

The authors aimed to explore taste distortion in patients with chronic kidney disease (CKD). One hundred and four patients were divided into a control group and a study group. The data was collected through a questionnaire and was statistically analyzed. The results showed that 28.7% of respondents had a loss of taste (96.60% CKD patients). There was a statistically significant correlation between the duration of treatment and taste loss, between patients' age and taste impairment, and between patients' age and the sense of a metallic taste in the mouth. Distortion in the sense of taste is an oral manifestation characteristic of CKD patients., (Copyright by Società Italiana di Nefrologia SIN, Rome, Italy.)

Published
2017

21. Effects of carob-bean gum thickened formulas on infants' reflux and tolerance indices.

Author

Georgieva M, Manios Y, Rasheva N, Pancheva R, Dimitrova E, and Schaafsma A

Abstract

Aim: To examine the effect of carob-bean gum (CBG) thickened-formulas on reflux and tolerance indices in infants with gastro-esophageal reflux (GER)., Methods: Fifty-six eligible infants (1-6 mo old) were randomly allocated to receive for two weeks a formula with either 0.33 g/100 mL (Formula A) or 0.45 g/100 mL (Formula B) of cold soluble CBG galactomannans respectively, or a formula with 0.45 g/100 mL of hot soluble CBG galactomannans (Formula C). No control group receiving standard formula was included in the study. Data on the following indices were obtained both at baseline and follow-up from all study participants: 24 h esophageal pH monitoring indices, anthropometrical indices (i.e., body weight and length) and tolerance indices (i.e., frequency of colics; type and frequency of defecations). From the eligible infants, forty seven were included in an intention-to-treat analysis to examine the effects of the two-week trial on esophageal 24 h pH monitoring, growth and tolerance indices. Repeated Measures ANOVA was used to examine the research hypothesis., Results: Regarding changes in 24 h pH monitoring indices, significant decreases from baseline to follow-up were observed in the "Boix Ochoa Score" (i.e., an index of esophageal acid exposure), in the total number of visible refluxes and in all symptoms related indices due to acid reflux only for infants provided with Formula A, while no significant changes were observed for infants provided with Formulas B and C. In addition, the significant decreases observed in two symptoms related pH monitoring indices (i.e., "Symptom index for reflux" and "Percentage of all reflux") for infants provided with Formula A were also found to differentiate significantly compared to the changes observed in the other two groups (P = 0.048 and P = 0.014 respectively). Concerning changes in anthropometric indices, body weight significantly increased among infants provided with Formulas A and C, but not for infants provided with Formula B. As far as tolerance indices were concerned, the numbers of total and diarrheic defecations increased significantly only in infants provided with Formula B and these changes were significantly higher compared to the decreases observed in infants fed with Formulas A and C (P = 0.003 and P = 0.015 respectively. Lastly the number of colics significantly decreased in all infants, irrespective of the tested formula., Conclusion: Formula A (i.e., 0.33 g/100 mL of cold galactomannans) was effective in reducing certain pH-monitoring indices of uncomplicated GER, increased body weight and was well-tolerated by infants.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results